AEON Biopharma Taps Former FDA Neuroscience Leader as Acting Chief Regulatory Officer
Event summary
- AEON Biopharma appoints Paul Lee, M.D., Ph.D., former FDA neuroscience leader, as acting Chief Regulatory Officer.
- Dr. Lee previously advised AEON on regulatory strategy for ABP-450 through Clintrex Research LLC.
- ABP-450 is a biosimilar to BOTOX® (onabotulinumtoxinA) targeting the $3.0B+ U.S. therapeutic neurotoxin market.
- Dr. Lee served as Deputy Director of the FDA’s Office of Neuroscience from May 2024 to June 2025.
- AEON aims to advance ABP-450 under the 351(k) biosimilar pathway.
The big picture
AEON Biopharma’s appointment of Dr. Paul Lee underscores the critical role of regulatory expertise in advancing biosimilars. The move comes as the biopharmaceutical industry faces increasing pressure to reduce healthcare costs through biosimilar alternatives. AEON’s focus on the $3.0B+ U.S. therapeutic neurotoxin market highlights the strategic importance of securing regulatory approval for ABP-450, which could disrupt the dominance of BOTOX in this space.
What we're watching
- Regulatory Alignment
- How Dr. Lee’s FDA experience will influence AEON’s interactions with the agency and the pace of ABP-450’s approval.
- Biosimilar Strategy
- Whether AEON can successfully navigate the 351(k) pathway and secure full-label access for ABP-450.
- Market Competition
- The impact of AEON’s biosimilar strategy on the $3.0B+ U.S. therapeutic neurotoxin market dominated by BOTOX.